Inaugural IssueVol. 1 No. 1 (2020)
The Inaugural Issue of IJVTPR opens with global vaccine controversies accented by the on-going pandemic of COVID-19. Shaw shows how the valued peer review process has been hijacked by the "conflicted commercialization of medicine" to remove studies from academic publications that do not conform to vested interests. Oller et al. follow up on the 2013-2015 WHO tetanus campaign used to distribute anti-fertility vaccine to the millions of African women seeking only to protect themselves and their babies from tetanus. David Lewis shows how biolsolids containing highly concentrated toxicants and pathogens from vaccines in human waste, are almost certainly contributing to the rising global prevalence of certain disorders and diseases. Sin Hang Lee examines cetain alignment issues in gene editing for Gardasil9 to produce virus-linked proteins that stimulate immunity against the 9 selected HPVs.
Our next issue of IJVTPR will focus on gene-editing research by vaccine developers that is cryptically called “dual use” or “gain of function” research manipulating potential pandemic pathogens (PPPs). In such PPP work, vaccine developers create gene-edited viruses from flu virions, SARS, MERS, corona viruses, etc., deliberately making them more infectious. For instance, they may create or import a "spike protein" to by-pass existing defenses in lab animals or humans. The ostensible goal of developing vaccines to protect against PPPs, is offset by actors seeking bioweapons, and by ways PPP research can and does sometimes go wrong. In the next issue, we will show why "dual use" PPP research may well have been the proximate cause of the still on-going global COVID-19 pandemic.